Skip to main content
SpringerLink
Log in

Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer

  • Living reference work entry
  • First Online:
Handbook of Oxidative Stress in Cancer: Therapeutic Aspects

  • 8 Accesses

Abstract

Chemotherapeutic intervention remains to be the most applicable approach in cancer after radiotherapy and surgery. Anticancer therapy based on oxidative damage through accumulation of ROS or defective antioxidant systems are developed for decades. After chemotherapeutic intervention, the relapse of cancer is common and the understanding of the causes of relapse are mostly unknown. The genetic information to generate and modulate ROS added valuable information on cancer relapse and are being explored with new genetic tools. Identifying cancer-specific mutations in a patient and treating them with mutation-specific drug will prevent the relapse of the disease and help to develop personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210–216

    Article  CAS  PubMed  Google Scholar 

  • Bechtel W, Bauer G (2009) Catalase protects tumor cells from apoptosis induction by intercellular ROS signaling. Anticancer Res 29(11):4541–4557

    CAS  PubMed  Google Scholar 

  • Bertholee D, Maring JG, van Kuilenburg AB (2017) Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet 56(4):317–337

    Article  CAS  PubMed  Google Scholar 

  • Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21(9)

    Google Scholar 

  • Burhans WC, Heintz NH (2009) The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47(9):1282–1293

    Article  CAS  PubMed  Google Scholar 

  • Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK, Kohno K, Mitra S, Bhakat KK (2008) Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol Cell Biol 28(23):7066–7080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cloos J, Nieuwenhuis EJ, Boomsma DI, Kuik DJ, van der Sterre ML, Arwert F, Snow GB, Braakhuis BJ (1999) Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 91(13):1125–1130

    Article  CAS  PubMed  Google Scholar 

  • Cloos J, de Boer WP, Snel MH, van den Ijssel P, Ylstra B, Leemans CR, Brakenhoff RH, Braakhuis BJ (2006) Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes. Mol Cancer Res 4(2):71–77

    Article  CAS  PubMed  Google Scholar 

  • Cronin-Fenton DP, Damkier P (2018) Tamoxifen and CYP2D6: a controversy in pharmacogenetics. Adv Pharmacol 83:65–91

    Article  CAS  PubMed  Google Scholar 

  • Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai C, Kovacs GT (2014) Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol 166(3):410–420

    Article  CAS  PubMed  Google Scholar 

  • Deeb D, Gao X, Jiang H, Janic B, Arbab AS, Rojanasakul Y, Dulchavsky SA, Gautam SC (2010) Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol 79(3):350–360

    Article  CAS  PubMed  Google Scholar 

  • Deeken JF, Figg WD, Bates SE, Sparreboom A (2007) Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anti-Cancer Drugs 18(2):111–126

    Article  CAS  PubMed  Google Scholar 

  • DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Di Paolo A, Polillo M, Capecchi M, Cervetti G, Baratè C, Angelini S, Guerrini F, Fontanelli G, Arici R, Ciabatti E, Grassi S, Bocci G, Hrelia P, Danesi R, Petrini M, Galimberti S (2014) The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14(4):328–335

    Article  PubMed  CAS  Google Scholar 

  • Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH, Badner JA (2004) Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64(12):4353–4356

    Article  CAS  PubMed  Google Scholar 

  • Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, Dolan ME (2007) Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 67(11):5425–5433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 18(6):515–523

    Article  CAS  PubMed  Google Scholar 

  • El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R, Gali-Muhtasib H (2010) Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15(2):183–195

    Article  CAS  PubMed  Google Scholar 

  • Hartford CM, Dolan ME (2007) Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 8(9):1159–1168

    Article  CAS  PubMed  Google Scholar 

  • Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC (2008) Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 66(6):826–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34(4):176–188

    Article  CAS  PubMed  Google Scholar 

  • Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53

    Article  CAS  PubMed  Google Scholar 

  • Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME (2008) Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7(9):3038–3046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iachetta F, Bonelli C, Romagnani A, Zamponi R, Tofani L, Farnetti E, Nicoli D, Damato A, Banzi M, Casali B, Pinto C (2019) The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. Br J Cancer 120(8):834–839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jamhiri I, Saadat I, Omidvari S (2017) Genetic polymorphisms of superoxide dismutase-1 A251G and catalase C-262T with the risk of colorectal cancer. Mol Biol Res Commun 6(2):85–90

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, Topcuoglu N, Aksoylar S, Cinar M, Tetik A, Eroglu Z (2009) Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 50(6):912–917

    Article  CAS  PubMed  Google Scholar 

  • Kim SJ, Kim HS, Seo YR (2019) Understanding of ROS-inducing strategy in anticancer therapy. Oxidative Med Cell Longev 2019:5381692

    Article  Google Scholar 

  • Knights J, Sato Y, Kaniwa N, Saito Y, Ueno H, Ramanathan M (2014) Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity. Pharmacogenet Genomics 24(1):15–25

    Article  CAS  PubMed  Google Scholar 

  • Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA (2011) Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 71(15):5081–5089

    Article  CAS  PubMed  Google Scholar 

  • Kuilenburg ABPV, Meijer J, Tanck MWT, Dobritzsch D, Zoetekouw L, Dekkers LL, Roelofsen J, Meinsma R, Wymenga M, Kulik W, Büchel B, Hennekam RCM, Largiadèr CR (2016) Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta 1862(4):754–762

    Article  PubMed  CAS  Google Scholar 

  • Ladiges W, Wanagat J, Preston B, Loeb L, Rabinovitch P (2010) A mitochondrial view of aging, reactive oxygen species and metastatic cancer. Aging Cell 9(4):462–465

    Article  CAS  PubMed  Google Scholar 

  • Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B (2007) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8(6):567–575

    Article  CAS  PubMed  Google Scholar 

  • Li MX, Shan JL, Wang D, He Y, Zhou Q, Xia L, Zeng LL, Li ZP, Wang G, Yang ZZ (2012) Human AP endonuclease 1 translocalizes to mitochondria after photodynamic therapy and protects cells from apoptosis. Cancer Sci 103:882

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liou GY, Storz P (2010) Reactive oxygen species in cancer. Free Radic Res 44(5):479–496

    Article  CAS  PubMed  Google Scholar 

  • Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y (2013) Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res 19(4):938–948

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maiti AK (2010) Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J 10(2):94–104

    Article  CAS  PubMed  Google Scholar 

  • Maiti AK (2012) Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells. Int J Cancer 130(1):1–9

    Article  CAS  PubMed  Google Scholar 

  • Maiti AK (2013) Overcoming drug resistance through elevation of ROS in cancer. Springer Publications

    Google Scholar 

  • Marsh S, Ameyaw MM, Githang’a J, Indalo A, Ofori-Adjei D, McLeod HL (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 16(6):528

    Article  CAS  PubMed  Google Scholar 

  • Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinksy E, Jones GD, Roninson IB, Macip S (2012) Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem

    Google Scholar 

  • Meeran SM, Patel SN, Tollefsbol TO (2010) Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 5(7):e11457

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, Tang Z, Zumbo P, Li S, Zavadil J, Levine RL, Cardozo T, Hunger SP, Raetz EA, Evans WE, Morrison DJ, Mason CE, Carroll WL (2013) Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45(3):290–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miteva-Marcheva NN, Ivanov HY, Dimitrov DK, Stoyanova VK (2020) Application of pharmacogenetics in oncology. Biomark Res 8:32

    Article  PubMed  PubMed Central  Google Scholar 

  • Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424(6948):561–565

    Article  CAS  PubMed  Google Scholar 

  • Nguyen T, Sherratt PJ, Pickett CB (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43:233–260

    Article  CAS  PubMed  Google Scholar 

  • Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374(Pt 2):337–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pander J, Gelderblom H, Guchelaar HJ (2007) Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 8(9):1197–1210

    Article  CAS  PubMed  Google Scholar 

  • Pani G, Galeotti T, Chiarugi P (2010) Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 29(2):351–378

    Article  CAS  PubMed  Google Scholar 

  • Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L (2019) Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment. Genes (Basel) 10(3)

    Google Scholar 

  • Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR (2009) Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem 284(40):27721–27733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R (2010) The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation – why mitochondria are targets for cancer therapy. Mol Asp Med 31(2):145–170

    Article  CAS  Google Scholar 

  • Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11(12):1306–1313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spitz MR, Wu X, Mills G (2005) Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23(2):267–275

    Article  PubMed  Google Scholar 

  • Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, Fisher PB (2005) Unique aspects of MDA-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 24(51):7552–7566

    Article  CAS  PubMed  Google Scholar 

  • Syed Alwi SS, Cavell BE, Donlevy A, Packham G (2012) Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones

    Book  Google Scholar 

  • Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16(2):123–140

    Article  CAS  PubMed  Google Scholar 

  • Tengström M, Mannermaa A, Kosma VM, Soini Y, Hirvonen A, Kataja V (2014) MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen. Acta Oncol 53(6):769–775

    Article  PubMed  CAS  Google Scholar 

  • Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579–591

    Article  CAS  PubMed  Google Scholar 

  • Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando A (2013) Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 19(3):368–371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24(34):3834–3848

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, Imakado S, Kotsuji T, Otsuka F, Roop DR, Harada T, Engel JD, Yamamoto M (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35(3):238–245

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Yi J (2008) Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7(12):1875–1884

    Article  CAS  PubMed  Google Scholar 

  • Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 101(32):11809–11814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wigle TJ, Tsvetkova EV, Welch SA, Kim RB (2019) DPYD and fluorouracil-based chemotherapy: mini review and case report. Pharmaceutics 11(5)

    Google Scholar 

  • Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD (2020) Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat 43(11):628–636

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics and Genomics, Mydnavar, Troy, MI, USA

    Amit K. Maiti

Authors
  1. Amit K. Maiti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amit K. Maiti .

Editor information

Editors and Affiliations

  1. Dept Biochem & Biophysics, C-Block, University of Kalyani, Kalyani, West Bengal, India

    Sajal Chakraborti

Section Editor information

  1. Department of Toxicology, Jagiellonian University, Krakow, Poland

    Maria Walczak

  2. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Tapati Chakraborti

  3. Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

    Pulak Kar

  4. University of Burdwan, Bardhaman, West Bengal, India

    Somasri Dam

  5. Institute of Veterinary Physiology, Vetsuisse-Faculty of Zurich, Winterthurerstrasse, Switzerland

    Kuntal Dey

  6. Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA

    Muthusamy Kunnimalaiyaan

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Maiti, A.K. (2021). Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer. In: Chakraborti, S. (eds) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-16-1247-3_146-1

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-1247-3_146-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-1247-3

  • Online ISBN: 978-981-16-1247-3

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation